BMS and Ono expand deals for Orencia and Phase II anticancer antibody

Bristol-Myers Squibb and Ono Pharmaceuticals have agreed to expand their existing agreements for two products, giving BMS broader rights to an investigational anticancer antibody and granting Ono Japanese co-commercialisation rights to BMS's arthritis drug, Orencia (abatacept).